Is Sanofi making a move into obesity? French pharma invests $27M into Ventyx

For the past few years, Sanofi has stayed out of the obe­si­ty drug de­vel­op­ment bo­nan­za, tak­ing a wait-and-see ap­proach while keep­ing an eye on po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.